纤维化4指数预测左心室辅助装置患者血液相容性相关不良事件
本研究纳入224例接受左心室辅助装置(LVAD)治疗的晚期心衰患者,计算术前和术后纤维化4(FIB4)指数并分析其与临床事件的关系。术后FIB4指数显著下降,且在校正混杂因素后独立关联于复合事件(全因死亡和血液相容性相关不良事件,HRAEs)。以术后FIB4阈值1.45分组,高FIB4组HRAEs风险升高(P=0.0038),生存曲线无显著差异。
要点
- 术后FIB4指数独立关联LVAD患者全因死亡和HRAEs复合事件。
- 术后FIB4>1.45组HRAEs风险显著升高(P=0.0038)。
- 高FIB4组血管性血友病因子活性升高,INR变异性无显著差异。
核心结论
- FIB4指数作为肝纤维化标志物,可作为LVAD患者HRAEs的有价值预后指标。
研究设计与样本
- 研究纳入224例因晚期心力衰竭接受LVAD治疗的患者,术前和术后计算FIB4指数并分析其与临床事件关联。
主要发现
- LVAD植入后FIB4指数显著下降。
- 术后FIB4指数在校正混杂因素后独立关联复合事件(全因死亡和HRAEs)。
- 以术后FIB4阈值1.45分组,高FIB4组HRAEs风险升高(P=0.0038),生存曲线无显著差异。
- 高FIB4组血管性血友病因子活性升高,凝血酶原时间国际标准化比值变异性无显著差异。
关键数值与推荐
- 术后FIB4指数阈值1.45用于分组。
- 高FIB4组与HRAEs风险关联的P=0.0038。
临床怎么用
- LVAD患者术后可计算FIB4指数,高FIB4(>1.45)提示HRAEs风险升高,需加强监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aimed to explore the association between the liver fibrosis-4 (FIB4) index and clinical events, specifically haemocompatibility-related adverse events (HRAEs), in patients who underwent left ventricular assist device (LVAD) implantation. METHODS: The study involved patients who received LVADs for advanced heart failure (HF) treatment. FIB4 index was calculated both preoperatively and postoperatively, and its association with clinical events was examined, focusing on all-cause mortality and HRAEs, which included severe bleeding, cerebrovascular accidents, and intra-pump thrombosis. RESULTS: A total of 224 patients with LVAD were analyzed. The value of FIB4 index was significantly decreased after LVAD implantation, and the postoperative FIB4 index was independently associated with composite events, including all-cause death and HRAEs after adjustment of cofounders. Next, we clarified the association between postoperative FIB4 index and clinical events after LVAD implantation. Patients were divided into 2 groups based on a postoperative FIB4 index threshold of 1.45. The high FIB4 group was associated an elevated risk of HRAEs (P = 0.0038), with no significant difference in survival curves between the groups. Additionally, the high FIB4 group showed elevated von Willebrand factor activity, while no significant differences were found in prothrombin time international normalized ratio variability. CONCLUSIONS: FIB4 index, a liver fibrosis marker, serves as a valuable prognostic indicator for HRAEs in patients receiving LVAD support.
引用
- Kurihara T, Amiya E, Hatano M, et al. Fibrosis 4 Index Predicts Haemocompatibility-Related Adverse Events in Patients Using Left Ventricular Assist Devices. Eur J Cardiothorac Surg. 2025. PMID: 40880288. doi:10.1093/ejcts/ezaf291
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。